This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Pandemic Fails to Deter YTD Rally of These Top 5 US Behemoths
by Nalak Das
A handful of corporate behemoths has skyrocketed YTD. Some of these stocks carry a favorable Zacks Rank and have rallied more than 20% YTD.
Buy Pharma Giant AbbVie Stock for Growth, Income & Coronavirus Safety
by Benjamin Rains
All of this might make investors want to consider AbbVie for the second half of 2020 with coronavirus fears and volatility likely to linger...
The Zacks Analyst Blog Highlights: Visa, JPMorgan Chase, Bank of America, Chevron and Eli Lilly
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Visa, JPMorgan Chase, Bank of America, Chevron and Eli Lilly
3 Dividend Stocks to Buy for Second Half of 2020 for Coronavirus Safety
by Benjamin Rains
Check out these three stocks with solid dividend yields that appear ready to continue to weather the coronavirus economic downturn in the second half of 2020...
Top Analyst Reports for Visa, JPMorgan & Bank of America
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Visa (V), JPMorgan Chase (JPM) and Bank of America (BAC).
Eli Lilly (LLY) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Eli Lilly (LLY) closed at $162.72, marking a -0.07% move from the previous day.
Novartis Gets Positive CHMP View for Cosentyx Label Expansion
by Zacks Equity Research
Novartis' (NVS) Cosentyx gets positive CHMP opinion for moderate-to-severe plaque psoriasis in children and adolescents aged 6-18 years.
J&J (JNJ) Discontinues Phase III Study of Stelara for Lupus
by Zacks Equity Research
Johnson & Johnson (JNJ) discontinues phase III study of Stelara (ustekinumab) in systemic lupus erythematosus.
Is Eli Lilly and (LLY) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (LLY) Outperforming Other Medical Stocks This Year?
Appeals Court Rules Against J&J but Cuts Talc- Powder Verdict
by Zacks Equity Research
J&J (JNJ) faces thousands of lawsuits, which claim that its talc-based products, primarily its baby powders, cause cancer.
3 Stocks to Buy on New Drug Approvals by FDA
by Manaswita Ghosh Dutta
In May, the Food and Drug Administration approved as many as 13 new drugs, higher than the eight approved in the same month last year.
Patterson Companies (PDCO) Q4 Earnings Top Estimates, Up Y/Y
by Zacks Equity Research
Patterson Companies' (PDCO) fiscal fourth-quarter results reflect dismal performance by Dental and Animal Health segments.
AbbVie's (ABBV) sBLA for Botox Gets Acceptance From FDA
by Zacks Equity Research
AbbVie's (ABBV) sBLA for expanding the label of Botox for use in pediatric patients with neurogenic detrusor overactivity gets acceptance from the FDA.
Merck's Pneumococcal Vaccine Meets Goal in Two Adult Studies
by Zacks Equity Research
Merck's (MRK) development program on V114 comprises 16 studies, evaluating safety, tolerability and immunogenicity of V114 in a variety of patient populations.
Pfizer Begins Four Phase III Studies on Vaccine Candidates
by Zacks Equity Research
Pfizer (PFE) begins four phase III studies on vaccine candidates. EMA validates its label expansion application for Bavencio in first-line bladder cancer.
What's in Store for Patterson Companies' (PDCO) Q4 Earnings?
by Zacks Equity Research
Patterson Companies' (PDCO) fiscal fourth-quarter results are likely to reflect solid performance at Dental segment.
Innoviva (INVA) Looks Good: Stock Adds 8.9% in Session
by Zacks Equity Research
Innoviva (INVA) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
The Zacks Analyst Blog Highlights: Eli Lilly & Company, AstraZeneca, AbbVie and Bristol-Myers Squibb
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Eli Lilly & Company, AstraZeneca, AbbVie and Bristol-Myers Squibb
Pharma Stock Roundup: FDA Approvals to MRK, LLY, NVS and GSK's Drugs
by Kinjel Shah
FDA approves expanded labels of Merck (MRK), Novartis (NVS) and Glaxo (GSK) drugs and Lilly's (LLY) new insulin.
Buy These 4 Big Drugmakers to Keep Coronavirus Woes at Bay
by Kinjel Shah
Here we highlight four large drugmakers that can prove to be safe bets amid the coronavirus crisis.
PTC Therapeutics to Commence Phase II/III Coronavirus Study in US
by Zacks Equity Research
PTC Therapeutics (PTCT) gets an FDA sanction to begin a phase II/III study on its DHODH inhibitor PTC299 as a potential treatment of COVID-19. The study will start in the United States shortly.
The Zacks Analyst Blog Highlights: Procter & Gamble, Eli Lilly, Thermo Fisher Scientific, Costco Wholesale and Shopify
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Procter & Gamble, Eli Lilly, Thermo Fisher Scientific, Costco Wholesale and Shopify
Company News for Jun 17, 2020
by Zacks Equity Research
Companies in the news are: WW, LLY, CLIR, CVU
Novartis' (NVS) Cosentyx Gets FDA Nod for New Indication
by Zacks Equity Research
Novartis' (NVS) Cosentyx wins FDA approval for a fourth indication ??? active non-radiographic axial spondyloarthritis (nr-axSpA).
Lilly Gains as Verzenio Meets Early Breast Cancer Study Goal
by Zacks Equity Research
Lilly's (LLY) phase III study on Verzenio in HR+, HER2- early breast cancer met its primary endpoint of invasive disease-free survival.